CHRS earnings call for the period ending March 31, 2019.
News & Analysis: Coherus BioSciences
Guess which of these stocks could see big changes ahead.
The biosimilar leader announced preliminary sales data for its most important product.
CHRS earnings call for the period ending December 31, 2018.
The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.
Enthusiasm for the biopharma is wearing off despite its announcement of an important commercial milestone.
The biosimilar developer received some good news from a regulator.
On a day the indexes advanced, these stocks saw outsize gains. Here's why.
Shares jump after management lays out a road map for the year ahead.
The biosimilar company reported earnings and a challenge to Amgen.